Evenamide for schizophrenia treatment resistance
Summary
This 52-week clinical study is sponsored by Newron Pharmaceuticals. The study aims to see how a drug called Evenamide works in people with schizophrenia whose symptoms have not improved enough with their current medication. Evenamide will be tested as an extra treatment added to the antipsychotic medicine you are already taking. The goal of this study is to find out if Evenamide is safe and if it can help improve symptoms when used together with standard antipsychotic drugs.
Eligibility
Eligible ages: 18 to 80
Inclusion criteria:
Ages: 18 years, or older
Diagnosed with Schizophrenia with confirmation of treatment resistance.
Exclusion criteria:
Diagnosis of schizophreniform disorder
Diagnosis of schizoaffective disorder
Or other primary psychiatric diagnosis, such as bipolar disorder or major depressive
disorder
History or current diagnosis of ‘Substance Use Disorder’ e.g. currently abusing drugs or alcohol or has done so in the past year.
Has known suicidal risk.
Has insulin-dependent diabetes mellitus.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
University of Calgary Mathison Centre for Mental Health Research & Education TRW Building, 1st floor 403-210-6903
Principal investigator:
Thomas Raedler
Clinical trial:
Yes
REB-ID:
REB25-1040